it is time for Congress to act.

I think that is a very important point. I appreciate your making that before this committee today.

I appreciate the intent of Senator Johnson's bill--I think we all do--and I, certainly, support expanding access to experimental therapies for terminally ill patients.

one concern that I think that we are hearing here, today, is about a lack of access to information about which programs are available to help people who are facing these life-threatening conditions.

You should not have to beg the Federal Government for permission to save your life.

We all need to love the FDA, and not do fire-alarm, knee-jerk oversight.

We need to reauthorize the Creating Hope Act.

We are 25 years behind.

What do you think that those of us who are sitting over here on this side of the dais can do, either through legislation or, maybe, through partnering with the Administration, to improve patient access to new treatments or to new therapies?

And, I just want to say, to those of you who continue to lead a good fight... thank you. You are doing the Lord's work.

What actions do you think that Congress should take--that Senator Johnson and myself and our colleagues should take--either through legislation or through partnering with the administration, to improve patient access to new and potentially…

So, I just want to provide this as an example of how, from my perspective, I think, the goal is to create reasons for companies to start pediatric trials--get the denominator as big as possible.

We want you to use the tools that we have already given you. This is legislation that already exists.

In 2012, when the President signed FDASIA, that had a lot of support.

We must work together to find solutions that benefit all Americans.

I am fully supportive of 'Right to Try.'

Thank you for bringing this together this morning.

The compassionate use process needs to be expedited.